Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
PrECOG, LLC.
Charite University, Berlin, Germany
Wake Forest University Health Sciences
Alliance for Clinical Trials in Oncology
Shanghai Chest Hospital
UNICANCER
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
Massachusetts General Hospital
Intergroupe Francophone de Cancerologie Thoracique
University of Rochester
University Hospital, Lille
Second Affiliated Hospital of Nanchang University
Institut Bergonié
Guangzhou Medical University
Montefiore Medical Center
Tianjin Medical University Cancer Institute and Hospital
PrECOG, LLC.
University of Pittsburgh
Dana-Farber Cancer Institute
Swiss Cancer Institute
University of Illinois at Chicago
NRG Oncology
Beijing Cancer Prevention & Treatment Society
Big Ten Cancer Research Consortium
Sun Yat-sen University
University Health Network, Toronto
Intergroupe Francophone de Cancerologie Thoracique
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
H. Lee Moffitt Cancer Center and Research Institute
Abramson Cancer Center at Penn Medicine
Shanghai Junshi Bioscience Co., Ltd.
Mayo Clinic
Intergroupe Francophone de Cancerologie Thoracique
Memorial Sloan Kettering Cancer Center
University of Kentucky
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Latin American Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
University of Alabama at Birmingham
University Hospital, Essen
Shanghai Junshi Bioscience Co., Ltd.
University Health Network, Toronto
Cancer Institute and Hospital, Chinese Academy of Medical Sciences